Skip to main content
SpringerLink
Log in
Book cover

Sjögren’s Syndrome pp 441–453Cite as

Measurement of Quality of Life in Primary Sjögren’s Syndrome

  • Chapter
  • First Online:

Abstract

Primary Sjögren’s syndrome (PSS) is an immune-mediated rheumatic disease in which inflammation of secretory (exocrine) glands leads to dry eyes and dry mouth [1]. Dryness of other surfaces such as the skin, vagina, airways, and gastrointestinal tract also occurs. The secretory glands are infiltrated by collections (focal aggregations) of lymphocytes. In the salivary glands, these focal lymphocyte aggregations are typically clustered around the salivary ducts. Patients typically also complain of reduced well-being, fatigue, and arthralgia. Approximately three-quarters of patients have autoantibodies in their blood – anti-Ro and/or anti-La antibodies – and a majority also have elevated total immunoglobulin levels (hypergammaglobulinaemia).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Jonsson R, Bowman SJ, Gordon TP. Sjögren’s Syndrome. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions, Chapter 78. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1681–705.

    Google Scholar 

  2. Carr AJ, Thompson PW, Kirwan JR. Quality of life measures. Br J Rheumatol. 1996;35:275–81.

    Article  PubMed  CAS  Google Scholar 

  3. WHOQOL Group. Development of the WHOQOL: rationale and current status. Int J Ment Health. 1994;23:24–56.

    Google Scholar 

  4. WHOQOL Group. Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment. Psychol Med. 1998;28:551–8.

    Article  Google Scholar 

  5. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey. Manual and interpretation guide. Boston: The Health Institute, New England Medical Centre; 1993.

    Google Scholar 

  6. Thomas E, Hay EM, Hajeer A, Silman AJ. Sjogren’s syndrome: a community based study of prevalence and impact. Br J Rheumatol. 1998;37:1069–76.

    Article  PubMed  CAS  Google Scholar 

  7. Strömbeck B, Ekdahl C, Manthorpe R, et al. Health-related quality of life in primary Sjogren’s syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol. 2000;29:20–8.

    Article  PubMed  Google Scholar 

  8. Tensing EK, Solovieva SA, Tervahartiala T, et al. Fatigue and health profile in sicca syndrome of Sjogren’s and non-Sjogren’s syndrome origin. Clin Exp Rheumatol. 2001;19:313–6.

    PubMed  CAS  Google Scholar 

  9. Rostron J, Rogers S, Longman L, et al. Health-related quality of life in patients with primary Sjogren’s syndrome and xerostomia: a comparative study. Gerodontology. 2002;19:53–9.

    Article  PubMed  Google Scholar 

  10. Bowman SJ, Booth DA, Platts RG, UK Sjögren’s Interest Group. Measurement of fatigue and discomfort in primary Sjogren’s syndrome using a new questionnaire tool. Rheumatology (Oxford). 2004;43:758–64.

    Article  CAS  Google Scholar 

  11. Belenguer R, Ramos-Casals M, Brito-Zerón P, et al. Influence of clinical and immunological parameters on the health-related quality of life in patients with primary Sjogren’s syndrome. Clin Exp Rheumatol. 2005;23:351–6.

    PubMed  CAS  Google Scholar 

  12. Champey J, Corruble E, Gottenberg JE, et al. Quality of life and psychological status in patients with primary Sjogren’s syndrome and sicca symptoms without autoimmune features. Arthritis Rheum. 2006;55:451–7.

    Article  PubMed  Google Scholar 

  13. Stewart CM, Berg KM, Cha S, Reeves WH. Salivary dysfunction and quality of life in Sjogren’s syndrome: a critical oral-systemic connection. J Am Dent Assoc. 2008;139:291–9.

    PubMed  Google Scholar 

  14. López-Jornet P, Camacho-Alonso F. Quality of life in patients with Sjogren’s syndrome and sicca complex. J Oral Rehabil. 2008;35:875–81.

    Article  PubMed  Google Scholar 

  15. Meijer JM, Meiners PM, Huddleston Slater JJ, et al. Health-related quality of life, employment and disability in patients with Sjogren’s syndrome. Rheumatology (Oxford). 2009;48:1077–82.

    Article  Google Scholar 

  16. Segal B, Bowman SJ, Fox PC, et al. Primary Sjogren’s syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes. 2009;27:7–46.

    Google Scholar 

  17. Baturone R, Soto M, Marquez M, et al. Health-related quality of life in patients with primary Sjogren’s syndrome: relationship with serum levels of proinflammatory cytokines. Scand J Rheumatol. 2009;2:1–4.

    Google Scholar 

  18. Sutcliffe N, Stoll T, Pyke S, Isenberg D. Functional disability and end-organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjögren’s syndrome (SS), and primary SS. J Rheumatol. 1998;25:63–8.

    PubMed  CAS  Google Scholar 

  19. Group EuroQoL. EuroQoL – a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.

    Article  Google Scholar 

  20. Rajagopalan K, Abetz L, Mertzanis P, et al. Comparing the discriminative validity of two generic and one disease-specific health-related quality of life measures in a sample of patients with dry eye. Value Health. 2005;8:168–74.

    Article  PubMed  Google Scholar 

  21. Seror R, Ravaud P, Bowman S, et al. EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI): development of a consensus systemic disease activity index in primary Sjogren’s syndrome. Ann Rheum Dis. 2009;69:1103–9.

    Article  PubMed  Google Scholar 

  22. Ng WF, Griffiths B, Griffiths ID, Bowman SJ. United Kingdom primary Sjogren’s syndrome registry (UKPSSR). London: Medical Research Council; 2008.

    Google Scholar 

  23. Hunt SM, McEwan J. The development of a subjective health indicator. Sociol Health Illn. 1980;2:231–46.

    Article  PubMed  CAS  Google Scholar 

  24. Gilson BS, Gilson JS, Bergner M, et al. The sickness impact profile. Development of an outcome measure of health care. Am J Public Health. 1975;65:1304–10.

    Article  PubMed  CAS  Google Scholar 

  25. Valtysdottir ST, Gudbjornsson B, Lindqvist U, et al. Anxiety and depression in patients with primary Sjogren’s syndrome. J Rheumatol. 2000;27:165–9.

    PubMed  CAS  Google Scholar 

  26. Bowman SJ. Patient-reported outcomes including fatigue in primary Sjogren’s syndrome. Rheum Dis Clin North Am. 2008;34:949–62.

    Article  PubMed  Google Scholar 

  27. Bowman SJ, Booth DA, Platts RG, et al. Validation of the sicca symptoms inventory for clinical studies of Sjogren’s syndrome. J Rheumatol. 2003;30:1259–66.

    PubMed  Google Scholar 

  28. Slade GD, Spencer AJ. Development and evaluation of the Oral Health Impact Profile. Community Dent Health. 1994;11:3–11.

    PubMed  CAS  Google Scholar 

  29. Allen PF, McMillan AS, Walshaw D, Locker D. A comparison of the validity of generic and disease-specific measures in the assessment of oral health-related quality of life. Community Dent Oral Epidemiol. 1999;27:344–52.

    Article  PubMed  CAS  Google Scholar 

  30. Allen PF, McMillan AS, Locker D. An assessment of sensitivity to change of the Oral Health Impact Profile in a clinical trial. Community Dent Oral Epidemiol. 2001;29:175–82.

    Article  PubMed  CAS  Google Scholar 

  31. Lopez-Jornet P, Camacho-Alonso F. Quality of life in patients with Sjogren’s syndrome and sicca complex. J Oral Rehabil. 2008;35:875–81.

    Article  PubMed  CAS  Google Scholar 

  32. McMillan AS, Leung KC, Leung WK, et al. Impact of Sjogren’s syndrome on oral health-related quality of life in southern Chinese. J Oral Rehabil. 2004;31:653–9.

    Article  PubMed  CAS  Google Scholar 

  33. Larsson P, List T, Lundström I, et al. Reliability and validity of a Swedish version of the Oral Health Impact Profile (OHIP-S). Acta Odontol Scand. 2004;62:147–52.

    Article  PubMed  Google Scholar 

  34. Barcelos F, Patto JV, Parente M, et al. Applicability of sialometry and other instruments to evaluate xerostomia and xerophthalmia in a Sjogren’s syndrome outpatient clinic. Acta Reumatol Port. 2009;34:212–8.

    PubMed  Google Scholar 

  35. McGrath C, Bedi R, Bowling A. Evaluation of OHQoL-UK(c): a measure of oral health related quality of life. J Dent Res. 1999;78:1051.

    Google Scholar 

  36. Locker D, Matear D, Stephens M, et al. Comparison of the GOHAI and OHIP-14 as measures of the oral health-related quality of life of the elderly. Community Dent Oral Epidemiol. 2001;29:373–81.

    Article  PubMed  CAS  Google Scholar 

  37. Henson BS, Inglehart MR, Eisbruch A, Ship JA. Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncol. 2001;37:84–93.

    Article  PubMed  CAS  Google Scholar 

  38. Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615–21.

    PubMed  CAS  Google Scholar 

  39. Vitale S, Goodman LA, Reed GF, Smith JA. Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjogren’s syndrome-related dry eye. Health Qual Life Outcomes. 2004;2:44.

    Article  PubMed  Google Scholar 

  40. Mangione CM, Lee PP, Pitts J, et al. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). Arch Ophthalmol. 1998;116:1496–504.

    PubMed  CAS  Google Scholar 

  41. d’Elia HF, Bjurman C, Rehnberg E, et al. Interleukin 6 and its soluble receptor in a central role at the neuroendocrine interface in Sjogren’s syndrome: an exploratory interventional study. Ann Rheum Dis. 2009;68:285–6.

    Article  PubMed  Google Scholar 

  42. Hartkamp A, Geenen R, Bijl M, et al. Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sjogren’s syndrome. Ann Rheum Dis. 2004;63:1335–7.

    Article  PubMed  CAS  Google Scholar 

  43. Segal B, Thomas W, Rogers T, et al. Prevalence, severity and predictors of fatigue in subjects with primary Sjogren’s syndrome. Arthritis Rheum. 2008;59:1780–7.

    Article  PubMed  Google Scholar 

  44. Bowman SJ, Sutcliffe N, Isenberg DA, et al. Sjogren’s systemic clinical activity index (SCAI): a systemic disease activity measure for use in clinical trials in primary Sjogren’s syndrome. Rheumatology (Oxford). 2007;46:1845–51.

    Article  CAS  Google Scholar 

  45. Barry RJ, Sutcliffe N, Isenberg DA, et al. The Sjogren’s Syndrome Damage Index: a damage index for use in clinical trials and observational studies in primary Sjogren’s syndrome. Rheumatology (Oxford). 2008;47:1193–8.

    Article  CAS  Google Scholar 

  46. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomised studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000;107:631–9.

    Article  PubMed  CAS  Google Scholar 

  47. Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren’s syndrome. Arch Intern Med. 1999;159:174–81.

    Article  PubMed  CAS  Google Scholar 

  48. Kruize AA, Hené RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjogren’s syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993;52:360–4.

    Article  PubMed  CAS  Google Scholar 

  49. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren’s syndrome. Results of the randomised, controlled trial of Remicade in primary Sjogren’s syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270–6.

    Article  PubMed  CAS  Google Scholar 

  50. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label phase II study. Arthritis Rheum. 2005;52:2740–50.

    Article  PubMed  CAS  Google Scholar 

  51. Meijer JM, Pijpe J, Vissink A, et al. Treatment of primary Sjogren’s syndrome with rituximab: extended follow-up, safety and efficacy of treatment. Ann Rheum Dis. 2009;68:284–5.

    Article  PubMed  CAS  Google Scholar 

  52. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjogren’s syndrome after two infusions of rituximab (anti CD20). Arthritis Rheum. 2007;57:310–7.

    Article  PubMed  CAS  Google Scholar 

  53. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren’s syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67:1541–4.

    Article  PubMed  CAS  Google Scholar 

  54. Hartkamp A, Geenen R, Godaert GL, et al. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren’s syndrome: a randomised controlled trial. Ann Rheum Dis. 2008;67:91–7.

    Article  PubMed  CAS  Google Scholar 

  55. van Woerkom JM, Kruize AA, Geenen R, et al. Safety and efficacy of leflunomide in primary Sjogren’s syndrome: a phase II pilot study. Ann Rheum Dis. 2007;66:1026–32.

    Article  PubMed  Google Scholar 

  56. Strombeck BE, Theander E, Jacobsson LT. Effects of exercise on aerobic capacity and fatigue in women with primary Sjogren’s syndrome. Rheumatology (Oxford). 2007;46:868–71.

    Article  CAS  Google Scholar 

Download references

Acknowledgements and Conflicts of Interest

WFN has received salary support from the Arthritis Research Campaign and grant support from the Medical Research Council, Arthritis Research Campaign, British Sjögren’s Syndrome Association and the JGW Patterson Foundation. The UK Primary Sjögren’s Syndrome Registry is funded by the Medical Research Council. SJB has consulted for Roche, Genentech, UCB, Glaxo-Smith-Kline and Astra-Zeneca and has received grant support from the Arthritis Research Campaign, University Hospital Birmingham Charities and the British Sjögren’s Syndrome Association.

Author information

Authors and Affiliations

  1. Rheumatology Department, University Hospital Birmingham (Selly Oak), Birmingham, UK

    Simon J. Bowman

  2. Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK

    Wan-Fai Ng

Authors
  1. Simon J. Bowman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wan-Fai Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Barcelona, Surgey, Hospital Clinic, Calle Villarroel, 170, Barcelona, 08036, Spain

    Manuel Ramos-Casals

  2. Massachusetts General Hospital, Boston, 02114, Massachusetts, USA

    John H. Stone

  3. National University of Athens, Athens, Greece

    Haralampos M. Moutsopoulos

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag London Limited

About this chapter

Cite this chapter

Bowman, S.J., Ng, WF. (2011). Measurement of Quality of Life in Primary Sjögren’s Syndrome. In: Ramos-Casals, M., Stone, J., Moutsopoulos, H. (eds) Sjögren’s Syndrome. Springer, London. https://doi.org/10.1007/978-0-85729-947-5_31

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-947-5_31

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-946-8

  • Online ISBN: 978-0-85729-947-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation